questionText: To ask the Secretary of State for Health and Social Care, what discussions he has had with Selective Serotonin Reuptake Inhibitors (SSRIs) manufacturers on the effectiveness of the packaging and labelling of SSRIs in warning patients of (a) the associated risks, (b) suicidal thoughts as a side effect of their use and (c) withdrawal symptoms.
answerText: The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that selective serotonin reuptake inhibitor (SSRI) packaging and labelling produced by marketing authorisation holders (MAHs) reflects what is known about the safet...
heading: Selective Serotonin Reuptake Inhibitors: Labelling and Packaging